Quantity Add to cart Inquiry
| Product Name | Chimeric HLA-A*02:01 (mα3) &mB2M&NY-ESO-1 (SLLMWITQC) Monomer |
| Cat. No. | MHCRP-0466 |
| Category | Proteins & Peptides |
| Product Description | Recombinant Chimeric HLA-A*02:01 (mα3) &mB2M&NY-ESO-1 (SLLMWITQC) Monomer Protein is expressed from HEK293 with His tag at the C-terminus. It contains Gly25-Thr206 (Human HLA-A*02:01 α1&α2) and Asp207-Glu299 (Mouse H-2Ld α3), Ile21-Met119 (mB2M) and SLLMWITQC peptide. |
| Size | 100/500 μg |
| Format | Liquid. Supplied as 0.22 μm filtered solution in PBS (pH 7.4). |
| Storage | Store at -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |
| Shipping Temp | Shipped with dry ice. |
| Lead Time | Product delivery time depends on the supplier. |
| Species | Human&Mouse |
| Expression Host | HEK293 |
| Accession No | A0A140T913(Human HLA-A*02:01 α1&α2)&P01897(Mouse H-2Ld α3)&P01887(Mouse B2M)&SLLMWITQC |
| Tag | C-His |
| Tag Position | C-terminus |
| Molecular Type | Monomer |
| Molecular Weight (MV) | The protein has a predicted MW of 48.02 kDa. Due to glycosylation, the protein migrates to 50-65 kDa based on Bis-Tris PAGE result. |
| Gene Synonyms | MHC; MY-ESO-1; CT6.1; LAGE-2; CTAG1; CTAG1B; ESO1CTAG; LAGE2A; NY-ESO-1; CTAG1A |
| Purity | > 95% as determined by Bis-Tris PAGE. |
| Amino Acid Range | Gly25-Thr206 (Human HLA-A*02:01 α1&α2) & Asp207-Glu299 (Mouse H-2Ld α3), Ile21-Met119 (mB2M), and SLLMWITQC peptide |
| Activity | Immobilized anti-HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) antibody, hFc tag at 5 μg/mL (100 μL/well) on the plate. Dose response curve for chimeric HLA-A*02:01 (mα3) &mB2M&NY-ESO-1 (SLLMWITQC) monomer, His tag with the EC50 of 23.0 ng/mL determined by ELISA (QC Test). The affinity constant of 9.32 nM as determined in SPR assay. |
| Product Background | NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy. |
| Allele | HLA-A*02:01 |
| Biotinylated | No |
Tel:
One-stop service